2022: Market Development Period (Focus on Basic Intermediates + Supply Chain Optimization)
1. Strategic Cooperation Achievements
Signed a Long-term Supply Agreement for Pyridine Intermediates with India's Sun Pharmaceutical: Tailored to the needs of Sun Pharma's anti-infective drug production, supplied high-purity 2-chloropyridine and 3-aminopyridine with an annual supply volume of 2,500 tons and a contract value of 15 million US dollars. Leveraging China-India cross-border logistics corridors, achieved weekly cargo shipments, shortening the delivery cycle by 18 days compared with traditional routes, and became one of Sun Pharma's key Asian suppliers for pyridine series intermediates.
Co-built a GMP-compliant Warehousing & Distribution Center with Singapore's DKSH: Invested 4 million US dollars to establish a temperature-controlled warehousing facility in Singapore, specializing in the storage and distribution of moisture-sensitive pharmaceutical intermediates. Serving over 15 pharmaceutical manufacturers in Indonesia, Malaysia and the Philippines, the localized delivery ratio reached 35% that year, improving small-batch order fulfillment efficiency by 40%.
2. Export Scale Cases
Export of Aromatic Amine Intermediates to Southeast Asia: Exported p-nitroaniline, o-toluidine and other basic pharmaceutical intermediates to Vietnam, Thailand and Myanmar, with an annual export volume of 6,000 tons and an export value of 58 million RMB, achieving a year-on-year growth of 32%. The products meet BP/USP standards, supporting local generic drug production and helping reduce raw material costs by 12%-15% for partner enterprises.
Aliphatic Acid Intermediates Exported to Africa: Covering 7 countries including South Africa, Kenya and Nigeria, the annual export volume reached 4,200 tons with an export value of 41 million RMB. By adopting vacuum packaging and sea-air combined transportation, the product qualification rate during transportation reached 99.8%, making the company a leading Asian supplier in Africa's generic drug intermediate market.
3. Market Breakthrough Cases
First Entry into the European Generic Drug Market: Para-hydroxybenzoic acid intermediates passed EU GMP certification and EDQM quality inspection, successfully entering the supply chain of generic drug manufacturers in Spain and Portugal with an annual export volume of 900 tons, filling the gap in the company's high-standard pharmaceutical intermediate exports to Europe.
Cross-border RMB Settlement for Pharmaceutical Exports: In response to exchange rate volatility risks, promoted RMB settlement among customers in Russia, Turkey and Bangladesh, adding 12 new RMB-settled customers that year with a cumulative settlement amount exceeding 95 million RMB.
Comprehensive Warehouse Solutions
With a broad level of expertise, Crown can serve as the single point of contact for your warehouse project.
Warehouse Design Services
Expert space-planning consultation for your specific needs
Racking & Storage Solutions
A broad selection of products for a customized storage system
Warehouse Products
All the products you need to complete your warehouse set up
Contact Us
Contact Us Let's TalkYour Any Query
Subscribe For Newsletter!
Your Email...
